SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| STEM CELL SCIENCES PLC | 08/04/2009 |
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)name changed to Asset Realisation Company PLC | 08/04/2009 |
following completion of the sale of the trading subsidiaries of the Company and certain ancillary agreements, assets, properties and rights, the Company's name has now been changed to "Asset Realisation Company Plc". Please note that the Company's new website address is, www.assetrealco.com | 03/04/2009 |
company advises of the completion of the disposal of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights (the "Disposal"), in accordance with the terms of the Disposal Agreement ( "Completion") - pursuant to the terms of the Disposal Agreement, the Company received at Completion: (i) 2,120,000 StemCells, Inc. Shares; (ii) a waiver of circa $715,000 (being the amount owed by the Company in respect of the StemCells, Inc. Loans); and (iii) the contingent right to receive up to 530,000 further Stem Cells, Inc. Shares subject to the terms of the escrow arrangements | 02/04/2009 |
company announces that at the Company's Extraordinary General Meeting ("EGM") held on Friday, all resolutions were duly approved by shareholders, present in person or by proxy, by 99% of the votes cast representing 64% of the total issued share capital | 30/03/2009 |
provides Notice of an Extraordinary General Meeting of Stem Cell Sciences Plc, to be held at the offices of Daniel Stewart & Company Plc, 36 Old Jewry, London, EC2R 8DD, UK at 11.00 a.m. on 27 March 2009 | 03/03/2009 |
company announces that it has entered into a definitive agreement with StemCells, Inc. a publicly traded Delaware corporation (Nasdaq: STEM), for the sale of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights for a maximum total consideration of approximately US$4,849,000 | 03/03/2009 |
the company will not be filing its preliminary results for the year ended 31st December 2008 - this is due to the Company considering an offer on its operating subsidiaries (Stem Cell Sciences Holdings Limited, Stem Cell Sciences Australia (Pty) Limited and Stem Cell Sciences UK Limited) - Stem Cell Sciences intends to remain suspended until further notice | 26/02/2009 |
directors believe that, given the current investment climate, the Company will deliver better shareholder value by selling substantially all of its operating assets and liabilities - a further announcement on this is expected to be made shortly | 11/02/2009 |
announces the signing of a further licence to its IRES technology - the undisclosed licensee is a major research-based international pharmaceutical company in the top 20 by market capitalisation and annual sales and it will use the technology in its own research and development activities - financial terms are not disclosed for this fully paid-up licence, which was signed during the Christmas holiday period | 05/01/2009 |
company announces that it has received 200,000 by way of a secured loan for working capital purposes - in exchange the third party lender has been granted a period of exclusivity to conduct further due diligence in respect of the Company's business and assets | 29/12/2008 |
the Company is still in discussions with a number of third parties about various options, including possible refinancing, divestiture of certain operations and/or merger opportunities of the Company, which may include an offer for the Company. There can be no certainty that any of the above transactions will proceed or that an offer will be made for the Company or as to the terms on which any such offer might be made. As a result of this announcement the Company is now in an Offer Period under the rules of the United Kingdom Takeover Code | 09/12/2008 |
the securities of Stem Cell Sciences Plc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 26/11/2008 |
suspension of trading in the securities of Stem Cell Sciences Plc (the "Company") will be lifted immediately, following receipt of the Company's Full Year Accounts for the period ended 31 December 2007 | 02/04/2008 |
shares suspended from quotation following failure to lodge full year accounts for the period ended 31 December 2007 | 01/04/2008 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Alastair Riddell | Executive Director | 19/11/2007 |
| David Newton | Company Secretary | |
| Sue Furber | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
